Board of Directors
Carl Borrebaeck (1948), Chairman
Professor Carl Borrebaeck is a successful entrepreneur and founder of Immunovia, who also founded Senzagen AB (Publ.) (SENZA; Nasdaq First North), BioInvent International AB (Publ.) (BINV; Nasdaq Stockholm), and Alligator BioScience AB (Publ.) (ATORX; Nasdaq Stockholm) and PainDrainer AB. In 2009, he was awarded the AkzoNobel Science Prize and in 2012 he received the Royal Swedish Academy of Engineering’s gold medal for his pioneering research on biomarkers, and in 2017 he was named Biotech Builder of the Year for his entrepreneurship. He is a life member of the IVA (Royal Swedish Academy of Engineering Sciences), a director of CREATE Health – the Strategic Division of Translational Cancer Research and former Deputy Vice-Chancellor of Lund University (responsible for its innovation systems and industrial partnerships) and Head of the Department of Immunotechnology. He is also the Founding Mentor for NOME (Nordic Mentor Network for Entrepreneurship).
Immunovia has signed an agreement with CB Ocean Capital AB regarding services to be performed by Carl Borrebaeck. He will provide the company with services focused on providing scientific and strategic support to the company, for example at scientific presentations and conferences. The services provided do not include tasks related to board assignments. Under the agreement, CB Ocean Capital AB will receive remuneration of SEK 31,500 per quarter, excluding additional social security contributions and value added tax, for work performed by Carl Borrebaeck for the company. The agreement runs from January 1, 2018 until further notice with three months of mutual notice.
Current assignments: Chairman of SenzaGen AB and CB Ocean Capital AB. Board member of Alligator Bioscience AB and Scandion A/S. Managing partner of Immunova Handelsbolag.
Previous assignments (last five years): Chairman of LU Innovation System AB. Board member of Atlas Therapeutics AB, BioInvent International Aktiebolag, LU Holding AB, Medicon Village Fastighets AB, WntResearch AB and Clinical Laserthermia AB. Deputy director of Endo Medical AB.
Ann-Christine Sundell (1964)
Ann-Christine Sundell holds an M.Sc. in biochemistry and has over 30 years’ experience of global commercial positions in the diagnostics sector. She was EVP of Genetic Screening at PerkinElmer, one of the world’s largest life science companies, for ten years, where she led one of the company’s five strategic business areas with over 1,500 employees worldwide. She has rigorous strategic and operational experience in all segments significant to Immunovia including Sales & Marketing, R&D, Production, Quality and regulatory issues.
Ann-Christine has strategic and operational experience from areas where Immunovia is active such as Sales & Marketing, R&D, production, quality and compliance.
Current assignments:Board member, chairman of nomination and remuneration committees and member of audit committee for Revenio Group Oy. Chairman of the board of Medix Biochemica Group Oy. Board member and member of remuneration and nomination committees for Biocartis NV. Vice Chairman of the board and chairman of nomination committee for Raisio Oy. Board member of Förlags Ab Sydvästkusten. Holder of AConsult.
Previous assignments (last five years): Chairman of Oy Medix Biochemica Ab. Board member of Minervastiftelsen, Oy Medix Ab, Bueprint Genetics Oy, Serres Oy, Ledil Group Oy, Ledil Oy and Zymonostics ApS.
Hans Johansson (1954)
Hans Johansson holds an M.Sc. (Eng.) in chemical engineering and has long-term experience and a broad-based contact network from previous roles in the life science and diagnostic industries, most recently as Vice President of Companion Diagnostics in Thermo Fisher’s Specialty Diagnostics Group. Prior to that, his positions included serving as Global VP and Head of Marketing & Commercial Development for Thermo Fisher’s ImmunoDiagnostics Division and VP of Pharmacia Biotechnology AB’s Laboratory business area. He has also served as the President, Director and entrepreneur of various start-ups in the sector. He has over 30 years’ experience of global business development and commercialization of biotech and diagnostic innovations.
Current assignments: Chairman of Doloradix AB och Myrtila AB. Board member of QLinea AB
Previous assignments (last five years): Deputy Director of Duvbo affärskonsult AB. Board member of Uppsala Innovation Centre AB.
Peter Høngaard Andersen (1956)
Dr. Peter Høngaard Andersen holds a B.Sc. in Chemistry, an M.Sc. in Biochemistry, is an M.D. and has many years’ experience and a broad network from his previous positions within the Life Science and biotech industries. Dr. Høngaard Andersen also has many years’ experience in pharmaceutical research and development from the pharmaceutical industry: 14 years at Novo Nordisk in CNS, neuroendocrinology, women’s health and type-2 diabetes and 15 years at Lundbeck in CNS pharmaceutical research and early development. Dr. Høngaard Andersen has been involved in the research and development of several pharmaceuticals on the market (e.g. Norditropine, Simplex, Victoza, Trintellix / Brintellix, Cipralex).
Dr. Høngaard Andersen has been a founder or co-founder of several biotech companies, including Acadia Pharmaceuticals, Zealand Pharma, Glycom, Serendex, Epitherapeutics and Prexton Pharmaceuticals. Dr. Høngaard Andersen was involved in the Innovative Medicines Initiative (IMI) from its inception in 2003 and served as Chairman of the industry side of IMI from 2009–2014. In addition, Dr Høngaard Venture is a Partner in Ysios Capital and a member of the Advisory Board in Eir Ventures.
Current assignments: Chairman of Scandion Oncology A/S and the Innovation Board of the Danish Regional Council and a board member of Immunovia AB. In addition, Dr Høngaard is a Venture Partner in Ysios Capital and a member of the Advicisory Board in Eir Ventures.
Previous assignments (last five years): Founder and former CEO of Innovation Fund Denmark, member of the Executive Committee of IC Permed (the International Consortium of Personalized Medicine) and Chairman of Prexton Therapeutics.
Christofer Sjögren (1966)
Christofer Sjögren has 15 years of experience from the finance industry as equity analyst at companies such as Carnegie, Danske Bank (Publ.) and Deutsche Bank (Publ.) based in Stockholm. He has also been an Investor Relations consultant at Citigate Stockholm (previously part of Huntsworth plc) and is Vice President of Trelleborg AB (Publ.) for ten years, and head of Trelleborg Investor Relations.
Current assignments: None
Previous assignments (last five years): Board member Trelleborg Group Treasury.
Mimmi Ekberg (1959)
Mimmi Ekberg has about 30 years’ experience from the pharmaceutical industry and 25 years’ experience within oncology. She has had various positions at both national and Nordic level with experience of successfully launching specialist pharmaceutical. She has extensive strategic and operational experience in Sales & Marketing in the field of oncology. She has over 10 years’ experience as business area manager from E. Merck, Amgen and today serves as business area manager at Oncology Nordic at Celgene, focusing on pancreatic cancer. Since 2021, she has been working as a consultant in the pharmaceutical industry, right now focusing on solid tumors. She is a trained nurse with an academic background within medical oncology from Lund University, clinical trials at Karolinska University Hospital’s oncology department and an Executive MBA from Stockholm University.
Current assignments: Consultant in the Pharma Industry.
Previous assignments (last five years): None
Martin Møller (1975)
Martin Møller has broad and deep experience in the international healthcare industry from more than 20 years at McKinsey & Company, a global management consultancy, where he was a leader in the Pharmaceuticals & Medical Products Practice until 2021. In that role, he advised companies on strategy, transformation and business development, as well as product development, launch and commercialization. Martin Møller has worked with many segments of the life science industry and across geographies. His experience includes both working with companies in the rapid growth phase and more established companies with global operations. Martin Møller will leave McKinsey in the summer of 2021. Martin’s university degree is in the humanities. He is a citizen of Denmark and the US.
Current assignments: Senior Partner, McKinsey & Company. Board member of Scandion Oncology A/S
Previous assignments (last five years): Chairman of McKinsey & Company Denmark P/S